OMGA News and Press, Omega Therapeutics Inc. From 02/28/22

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass. , Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology a...

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer Industry Veteran With Over Two Decades of Drug Development Experience Will Shepherd the Company's Transition Into the Clinic PR Newswire CAMBRIDGE, Mass. , Jan. 10, 2022 /PR...

Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...

Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 18, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering t...

Omega Therapeutics (NASDAQ:OMGA): Q3 GAAP EPS of -$0.57 misses by $0.06. As of September 30, 2021, the Company had cash and cash equivalents totaling $234.3 million, which include the net proceeds of $128.1 million from the Company's IPO. For further details see: Omega Therapeutics EPS ...

Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives -OTX-2002, the Company's Lead Program Targeting c-MYC for the Treatment of Hepatocellular Carcinoma, is Currently Advancing Through IND-Enabling Studies; Good Progress Across Br...

Omega Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 9, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic ap...

Ocugen (NASDAQ:OCGN) made it into the list of best healthcare performers this week as its development plans for the COVID-19 shot made progress in the U.S., while Cortexyme (NASDAQ:CRTX) lost more than a quarter of value after a disappointing outcome for an Alzheimer’s trial. The healt...

Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine - Collaboration to Leverage Omega Epigenomic Controllers™, a New Class of mRNA Therapeutics as Programmable Epigenetic Medicines, for Ocular Diseases by Targeting and...

Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference PR Newswire CAMBRIDGE, Mass. , Sept. 27, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering...